2023³â ´ëÇÑÇ÷¾×ÇÐȸ °ñ¼öÁõ½ÄÁ¾¾ç¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¿ò : 2023-10-14
±³À°ÀÏÀÚ : 2023-10-14
±³À°Àå¼Ò : ¼¼Á¾´ëÇб³ ´ë¾çAI¼¾Å¸ AIȦ
±³À°ÁÖÁ¦ : 2023³â ´ëÇÑÇ÷¾×ÇÐȸ °ñ¼öÁõ½ÄÁ¾¾ç¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¿ò
ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : °ñ¼öÁõ½ÄÁ¾¾ç¿¬±¸È¸
´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581
À̸ÞÀÏ : hematology@kams.or.kr
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú
Âü¼®¿¹»óÀÎ : 60¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í Àü¹®ÀÇ 50,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10¿ù 14ÀÏ AIȦ 10:00~10:40 Clinical relevance of mutation profile in MPN(meloproliferative neoplasm) diseases ½Å»õ¾Ï(¿¬¼¼ÀÇ´ë )
±³À°½Ã°£ 10¿ù 14ÀÏ AIȦ 10:40~11:20 Clincal significance of quantitative assay of JAK2 and other mutations ÀÌÁ¾¹Ì(°¡Å縯ÀÇ´ë )
±³À°½Ã°£ 10¿ù 14ÀÏ AIȦ 11:20~12:00 Review of MPN(meloproliferative neoplasm)-MDS(myelodysplastic syndrome) overlap disease Á¶¿µ¿í(¿ï»êÀÇ´ë )
±³À°½Ã°£ 10¿ù 14ÀÏ AIȦ 12:30~13:30 Interferon treatment in MPN(meloproliferative neoplasm) È«ÁؽÄ(¼¿ïÀÇ´ë )
±³À°½Ã°£ 10¿ù 14ÀÏ AIȦ 13:30~14:10 Differential diagnosis: secondary erythrocytosis and thrombocytosis °û´ëÈÆ(°¡Å縯ÀÇ´ë )
±³À°½Ã°£ 10¿ù 14ÀÏ AIȦ 14:10~14:50 Beyond hydroxyurea for the treatment of polycythemia vera and essential thrombocythemia ±èÁÖÇü(°æºÏÀÇ´ë )
±³À°½Ã°£ 10¿ù 14ÀÏ AIȦ 14:50~15:30 Beyond ruxolitinib for the treatment of myelofibrosis ÃÖÀºÁö(¿ï»êÀÇ´ë)